STOCK TITAN

NeuroBo Pharmaceuticals Inc - NRBO STOCK NEWS

Welcome to our dedicated news page for NeuroBo Pharmaceuticals (Ticker: NRBO), a resource for investors and traders seeking the latest updates and insights on NeuroBo Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NeuroBo Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NeuroBo Pharmaceuticals's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.18%
Tags
-
Rhea-AI Summary
NeuroBo Pharmaceuticals has entered into a term sheet with MThera Pharma to out-license the worldwide rights for NB-01 for the treatment of painful diabetic neuropathy, excluding Korea. The financial terms were not disclosed. NeuroBo believes that MThera's experience in manufacturing and clinical development makes it the perfect partner for NB-01's development. NB-01 has shown promising results in a phase 2 trial and MThera intends to advance it into the next phase of clinical development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.89%
Tags
none
-
Rhea-AI Summary
NeuroBo Pharmaceuticals announced that their drug candidate, DA-1726, has shown superior weight loss efficacy compared to competitors in preclinical testing. The drug also demonstrated positive effects on glycemic control and metabolic parameters. NeuroBo plans to advance DA-1726 to a phase 1 clinical trial for obesity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.08%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.05%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.92%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.21%
Tags
management
NeuroBo Pharmaceuticals Inc

Nasdaq:NRBO

NRBO Rankings

NRBO Stock Data

17.71M
4.71M
61.67%
1.37%
1.26%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Boston

About NRBO

neurobo pharmaceuticals, inc., a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases. its therapeutics programs include nb-01 for the treatment of painful diabetic neuropathy; nb-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and gemcabene, which is focused on developing and commercializing therapies for the treatment of dyslipidemia. neurobo pharmaceuticals, inc. was incorporated in 2017 and is headquartered in boston, massachusetts.